247 related articles for article (PubMed ID: 17889376)
1. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
Prince HE; Lapé-Nixon M; Audette C; Van Horn K
J Neuroimmunol; 2007 Oct; 190(1-2):165-9. PubMed ID: 17889376
[TBL] [Abstract][Full Text] [Related]
2. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of interferon beta: differences among products.
Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta.
Lapé Nixon M; Matud J; Yeh C; Prince HE
J Neuroimmunol; 2009 May; 210(1-2):104-7. PubMed ID: 19345423
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
7. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
Deisenhammer F; Schellekens H; Bertolotto A
J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
Massart C; Gibassier J; Oger J; Le Page E; Edan G
Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
[TBL] [Abstract][Full Text] [Related]
9. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
Vartanian T; Sölberg Sørensen P; Rice G
J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
[TBL] [Abstract][Full Text] [Related]
10. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
Lam R; Farrell R; Aziz T; Gibbs E; Giovannoni G; Grossberg S; Oger J
J Immunol Methods; 2008 Jul; 336(2):113-8. PubMed ID: 18511063
[TBL] [Abstract][Full Text] [Related]
11. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
Pachner AR; Cadavid D; Wolansky L; Skurnick J
Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
Sominanda A; Rot U; Suoniemi M; Deisenhammer F; Hillert J; Fogdell-Hahn A
Mult Scler; 2007 Mar; 13(2):208-14. PubMed ID: 17439886
[TBL] [Abstract][Full Text] [Related]
14. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients.
Gibbs E; Oger J
J Neuroimmunol; 2007 Oct; 190(1-2):146-50. PubMed ID: 17825927
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
Khan OA; Dhib-Jalbut SS
Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
[TBL] [Abstract][Full Text] [Related]
16. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
Pachner AR; Dail D; Pak E; Narayan K
J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.
Ross C; Clemmesen KM; Svenson M; Sørensen PS; Koch-Henriksen N; Skovgaard GL; Bendtzen K
Ann Neurol; 2000 Nov; 48(5):706-12. PubMed ID: 11079533
[TBL] [Abstract][Full Text] [Related]
18. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.
Gneiss C; Tripp P; Ehling R; Khalil M; Lutterotti A; Egg R; Mayringer I; Künz B; Berger T; Reindl M; Deisenhammer F
J Neuroimmunol; 2006 May; 174(1-2):174-9. PubMed ID: 16556466
[TBL] [Abstract][Full Text] [Related]
19. Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera.
Gilli F; van Beers M; Marnetto F; Jiskoot W; Bertolotto A; Schellekens H
J Immunol Methods; 2008 Jul; 336(2):119-26. PubMed ID: 18558408
[TBL] [Abstract][Full Text] [Related]
20. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
